GlobeNewswire

Eight International Companies Presented at the First Nasdaq International Designation Virtual Investor Conference

Dela

NEW YORK, June 06, 2017 (GLOBE NEWSWIRE) -- Nasdaq, Inc. (Nasdaq:NDAQ) completed its first Nasdaq International Designation Virtual Investor Conference on June 1, 2017. Participating companies of the Nasdaq International Designation program joined the online conference to present their current state of business to a broad audience and potential investors. The conference also provided individual and institutional investors an opportunity to engage with CEOs, CFOs, and IROs from a wide range of sectors globally.

Full conference and presentation materials are available at the following links:

Full Conference 
http://edge.media-server.com/m/p/tnqwsb3a

Qantas Airways Ltd - Australia 
ASX: QAN, OTC - Nasdaq International Select: QABSY
Alan Joyce - Chief Executive Officer
http://edge.media-server.com/m/p/tnqwsb3a/clip_start_position/57

Continental AG - Germany
ETR: CON, OTC - Nasdaq International Select: CTTAY
Klaus Paesler - Manager, Investor Relations
http://edge.media-server.com/m/p/tnqwsb3a/clip_start_position/1437

Cielo S.A.  - Brazil
SAO: CIEL3, OTC: CIOXY
Andre Cazotto - Investor Relations Manager
http://edge.media-server.com/m/p/tnqwsb3a/clip_start_position/2915

Cyberdyne Inc - Japan
TYO: 7779, OTC - Nasdaq International Select: CYBQY
Shinji Uga - Chief Financial Officer
http://edge.media-server.com/m/p/tnqwsb3a/clip_start_position/4532.5

BE Semiconductor Industries N.V. - Netherlands
Euronext Amsterdam: BESI, OTC - Nasdaq International: BESIY
Richard Blickman - Chief Executive Officer
http://edge.media-server.com/m/p/tnqwsb3a/clip_start_position/5568

Roxgold Inc. - Canada
TSX:ROXG, OTC - Nasdaq International: ROGFF
John Dorward - President, Chief Executive Officer and Director
http://edge.media-server.com/m/p/tnqwsb3a/clip_start_position/6963

Audio Pixels Holdings - Australia
ASX: AKP, OTC - Nasdaq International: ADPXY
Danny Lewin - Founder, Chief Executive Officer
http://edge.media-server.com/m/p/tnqwsb3a/clip_start_position/8177.5

Freshii Inc - Canada
TSE: FRII, OTC: FRHHF
Matt Corrin - Chief Executive Officer
http://edge.media-server.com/m/p/tnqwsb3a/clip_start_position/9370.5

About The Nasdaq International Designation 
Launched in December 2015, the Nasdaq International Designation program is designed for non-U.S.-based companies that have level 1 American Depository Receipts or shares that trade in the over-the-counter (OTC) market. The program offers a unique partnership with Nasdaq that provides member companies with Nasdaq's robust visibility offering which allows for greater access to US investors, and can potentially increase liquidity. The Nasdaq International Designation is home to a diverse range of companies in innovative industries across the globe. Total Market Cap of Member Companies exceeds $140B and program members hail from Australia, Japan, Germany, Brazil, Canada, the U.K., and the Netherlands.

As a comprehensive program, companies receive a full service offering that includes investor relations tools and services, as well as access to Nasdaq's visibility assets to enhance communication with the investment community. In the past year, members of the program were invited to the Nasdaq MarketSite with the opportunity to amplify their brand activities through different channels.

If you are interested in the Nasdaq International Designation Program, learn more at http://business.nasdaq.com/list/international-designation

About Nasdaq:
Nasdaq (Nasdaq: NDAQ) is a leading global provider of trading, clearing, exchange technology, listing, information and public company services. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 89 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to 3,800 total listings with a market value of $11.0 trillion. To learn more, visit: http://business.nasdaq.com

-NDAQG-

Nasdaq Media Relations Contact:
Stephanie Lowenthal
+1 (646) 441-5073
Stephanie.Lowenthal@nasdaq.com

Emily Pan
+1(646) 441-5120
emily.pan@nasdaq.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Nasdaq via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Immunicum AB (publ) Announces Upcoming Investor Events in January22.1.2019 08:30Pressmeddelande

Press Release 22 January 2019 Immunicum AB (publ) Announces Upcoming Investor Events in January Immunicum AB (publ; IMMU.ST) announced today that Carlos de Sousa, CEO of Immunicum, and other members of the management team will present at upcoming investor conferences in January. Biomed Investor Event by Invest Securities Date: January 22, 2019 Venue: Les Salons Hoche, 9 Avenue Hoche, Paris, France Redeye Fight Cancer Seminar Date: January 22, 2019 Presentation Time: 11.15 am CET Panel: 11.25 am CET Venue: Master Samuelsgatan 42, Stockholm, Sweden Aktiespararna - Stora Aktiedagen Date: January 29, 2019 Presentation Time: 8.30 - 9.00 am CET Panel: "Samtal om cancerbekämpning", 10:50 am CET Venue: Medicon Village, Scheelevägen 2, Lund, Sweden For more information, please contact: Carlos de Sousa, CEO, Immunicum Telephone: +46 (0) 31 41 50 52 E-mail: info@immunicum.com Michaela Gertz, CFO, Immunicum Telephone: +46 70 926 17 75 E-mail: ir@immunicum.com Media Relations Gretchen Schweitzer an

Immunicum AB (publ) meddelar idag kommande presentationstillfällen under januari22.1.2019 08:30Pressmeddelande

Pressmeddelande 22 januari 2019 Immunicum AB (publ) meddelar idag kommande presentationstillfällen under januari Immunicum AB (publ; IMMU.ST) meddelar idag att Immunicums VD, Carlos de Sousa och andra medlemmar av ledningsgruppen kommer presentera vid följande investerarevent under januari. Biomed Investor Event by Invest Securities Datum: 22 januari 2019 Plats: Les Salons Hoche, 9 Avenue Hoche, Paris, France RedEye Fight Cancer Seminar Datum: 22 januari 2019 Presentationstid: 11.15 am CET Panel: 11.25 am CET Plats: Master Samuelsgatan 42, Stockholm, Sweden Aktiespararna - Stora Aktiedagen Datum: 29 januari 2019 Presentationstid: 8.30 - 9.00 am CET Panel: "Samtal om cancerbekämpning", 10:50 am CET Plats: Medicon Village, Scheelevägen 2, Lund, Sweden För ytterligare information kontakta: Carlos de Sousa, VD, Immunicum Telefon: +46 (0) 31 41 50 52 E-post: info@immunicum.com Michaela Gertz, Finanschef, Immunicum Telefon: +46 (0) 70 926 17 75 E-post: ir@immunicum.com Media Relations Gretch

Immunicum AB (publ) meddelar att resultaten från den kliniska fas I/II-studien med ilixadencel vid långt framskriden levercancer publicerats i Frontiers in Oncology21.1.2019 08:30Pressmeddelande

Pressmeddelande 21 januari 2019 Immunicum AB (publ) meddelar att resultaten från den kliniska fas I/II-studien med ilixadencel vid långt framskriden levercancer publicerats i Frontiers in Oncology Immunicum AB (publ; IMMU.ST) meddelar idag att den slutliga analysen av data från den undersökande kliniska studien med ilixadencel hos patienter med långt framskriden levercancer har publicerats i tidskriften, Frontiers in Oncology . Dessa data bekräftar de tidigare meddelade positiva egenskaperna gällande säkerhet och tolerabilitet för ilixadencel, både när det ges som enda behandling och i kombination med första linjens standardbehandling, sorafenib. Dessutom påvisades ökade nivåer av tumörspecifika CD8+ T-celler i cirkulerande blod för en majoritet av de utvärderbara patienterna, vilket indikerar ett systemiskt immunologiskt svar. De fullständiga resultaten ger ytterligare insikter om ilixadencels verkningsmekanism, tecken på klinisk effekt samt viktig information som kommer att vara vägl

Immunicum AB (publ) Announces Publication of Phase I/II Clinical Trial Results of Ilixadencel in Advanced Hepatocellular Carcinoma in Frontiers in Oncology21.1.2019 08:30Pressmeddelande

Press Release 21 January 2019 Immunicum AB (publ) Announces Publication of Phase I/II Clinical Trial Results of Ilixadencel in Advanced Hepatocellular Carcinoma in Frontiers in Oncology Immunicum AB (publ; IMMU.ST) announced today that the final data analysis from the exploratory clinical study of ilixadencel in patients with advanced hepatocellular carcinoma (HCC) has been published in the journal, Frontiers in Oncology . The data confirms previously communicated positive safety and tolerability of ilixadencel when administered both alone and in combination with current first-line standard of care, sorafenib. In addition, the data demonstrate an increased frequency of tumor-specific CD8+ T cells in circulating blood for a majority of evaluable patients, indicating a systemic immune response. The complete results provide further insight on ilixadencel's mode of action, signs of clinical activity and important information that will guide the next stage of clinical development. As commun

Karolinska Development's portfolio company Modus Therapeutics completes enrollment in Phase II study with sevuparin7.1.2019 12:00Pressmeddelande

STOCKHOLM, January 7, 2019. Karolinska Development's portfolio company Modus Therapeutics announces that the patient enrollment has been completed in the Phase II study with sevuparin in patients with sickle cell disease (SCD). The results from the study is expected in mid 2019. Modus Therapeutic's randomized, double blind study contains 140 SCD-patients with Acute Vaso Occlusive Crisis (VOC). It compares intravenously administered sevuparin with placebo. The primary endpoint of the study is the demonstration of a reduced time to resolution of patient's VOC. Clincal sites across Europe and the Middle East took part in the study that was conducted in conjunction with Modus Therapeutics' co development partner Ergomed. SCD has a high unmet medical need as there are currently no approved therapies for VOCs. It is an inherited blood disorder that affects between 90,000 to 100,000 patients in the U.S. and is characterized by severely painful VOCs that lead to organ damage due to a lack of o

Karolinska Development's portfolio company Modus Therapeutics completes enrollment in Phase II study with sevuparin7.1.2019 12:00Pressmeddelande

STOCKHOLM, January 7, 2019. Karolinska Development's portfolio company Modus Therapeutics announces that the patient enrollment has been completed in the Phase II study with sevuparin in patients with sickle cell disease (SCD). The results from the study is expected in mid 2019. Modus Therapeutic's randomized, double blind study contains 140 SCD-patients with Acute Vaso Occlusive Crisis (VOC). It compares intravenously administered sevuparin with placebo. The primary endpoint of the study is the demonstration of a reduced time to resolution of patient's VOC. Clincal sites across Europe and the Middle East took part in the study that was conducted in conjunction with Modus Therapeutics' co development partner Ergomed. SCD has a high unmet medical need as there are currently no approved therapies for VOCs. It is an inherited blood disorder that affects between 90,000 to 100,000 patients in the U.S. and is characterized by severely painful VOCs that lead to organ damage due to a lack of o

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum